Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression

[1] Maisonneuve P(2000)Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study Am J kidney diseases: official J Natl Kidney Foundation 35 157-65

[2] Agodoa L(2011)The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrology, dialysis, transplantation: official publication of the european Dialysis and Transplant Association Eur Ren Association 26 414-30

[3] Gellert R(2011)The pathophysiology of IgA nephropathy J Am Soc Nephrology: JASN 22 1795-803

[4] Stewart JH(2021)Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression Kidney Int 100 1-s276

[5] Buccianti G(2019)Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy PLoS ONE 14 e0212254-7

[6] Lowenfels AB(2018)Serum levels of galactose-deficient immunoglobulin (ig) A1 and related immune complex are associated with disease activity of IgA nephropathy PLoS ONE 13 e0206865-12

[7] McGrogan A(2014)Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: a case control study Clin Exp Nephrol 18 770-56

[8] Franssen CF(2019)Galactose-deficient IgA1 as a candidate urinary polypeptide marker of IgA Nephropathy? PLoS ONE 14 e0214256-60

[9] de Vries CS(2016)A new equation to estimate glomerular filtration rate Dis Markers 2016 7806438-806

[10] Suzuki H(2009)The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility Ann Intern Med 150 604-41

[1] Maisonneuve P(2000)Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study Am J kidney diseases: official J Natl Kidney Foundation 35 157-65

[2] Agodoa L(2011)The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrology, dialysis, transplantation: official publication of the european Dialysis and Transplant Association Eur Ren Association 26 414-30

[3] Gellert R(2011)The pathophysiology of IgA nephropathy J Am Soc Nephrology: JASN 22 1795-803

[4] Stewart JH(2021)Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression Kidney Int 100 1-s276

[5] Buccianti G(2019)Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy PLoS ONE 14 e0212254-7

[6] Lowenfels AB(2018)Serum levels of galactose-deficient immunoglobulin (ig) A1 and related immune complex are associated with disease activity of IgA nephropathy PLoS ONE 13 e0206865-12

[7] McGrogan A(2014)Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: a case control study Clin Exp Nephrol 18 770-56

[8] Franssen CF(2019)Galactose-deficient IgA1 as a candidate urinary polypeptide marker of IgA Nephropathy? PLoS ONE 14 e0214256-60

[9] de Vries CS(2016)A new equation to estimate glomerular filtration rate Dis Markers 2016 7806438-806

[10] Suzuki H(2009)The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility Ann Intern Med 150 604-41